中国创新药企对外授权巨额交易捷报频传，科创医药ETF嘉实(588700)冲击3连涨

Core Insights - The Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index has shown a positive trend, with notable increases in constituent stocks such as Zhenhua Cell and Rongchang Biopharmaceutical [1][3] - The Jiashi Sci-Tech Medicine ETF has experienced significant trading activity and growth, leading in both scale and share increase among comparable funds [3][6] Market Performance - As of June 24, 2025, the Sci-Tech Innovation Board Biopharmaceutical Index rose by 0.82%, with Zhenhua Cell up by 9.46% and Rongchang Biopharmaceutical up by 4.23% [1] - The Jiashi Sci-Tech Medicine ETF recorded a turnover of 8.8% and a transaction volume of 18.05 million yuan, with an average daily transaction of 41.47 million yuan over the past month [3] Fund Growth - The Jiashi Sci-Tech Medicine ETF has seen a scale increase of 128 million yuan over the past year, leading among comparable funds [3] - The fund's net asset value has increased by 21.01% over the past year, with a historical one-year profit probability of 72.17% [3][6] Top Holdings - The top ten weighted stocks in the Sci-Tech Innovation Board Biopharmaceutical Index account for 51.6% of the index, with leading companies including United Imaging Healthcare and BeiGene [3][5] Industry Trends - Recent significant licensing deals in the Chinese innovative pharmaceutical sector include a $6 billion deal by 3SBio and a $5.33 billion strategic collaboration between CSPC and AstraZeneca [5][6] - Chinese innovative pharmaceutical companies are demonstrating competitive advantages in R&D efficiency and cost control, particularly in advanced technology fields such as ADC and cell therapy [6]